AR126153A1 - Una composición farmacéutica que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico - Google Patents
Una composición farmacéutica que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílicoInfo
- Publication number
- AR126153A1 AR126153A1 ARP220101577A ARP220101577A AR126153A1 AR 126153 A1 AR126153 A1 AR 126153A1 AR P220101577 A ARP220101577 A AR P220101577A AR P220101577 A ARP220101577 A AR P220101577A AR 126153 A1 AR126153 A1 AR 126153A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- indol
- pyrazole
- cyano
- isopropyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- IMBBXSASDSZJSX-UHFFFAOYSA-N 4-Carboxypyrazole Chemical compound OC(=O)C=1C=NNC=1 IMBBXSASDSZJSX-UHFFFAOYSA-N 0.000 title 1
- JLQQRYOWGCIMMZ-UHFFFAOYSA-N 1-(3-cyano-1-propan-2-ylindol-5-yl)pyrazole-4-carboxylic acid Chemical compound C=1C=C2N(C(C)C)C=C(C#N)C2=CC=1N1C=C(C(O)=O)C=N1 JLQQRYOWGCIMMZ-UHFFFAOYSA-N 0.000 abstract 3
- 201000001431 Hyperuricemia Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000024924 glomerular filtration Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940116269 uric acid Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico o una sal farmacéuticamente aceptable de este, y un método para tratar o prevenir una enfermedad relacionada con la hiperuricemia usándolo, y la composición farmacéutica de la presente invención puede reducir de manera eficaz la concentración de ácido úrico en sangre en un paciente con una enfermedad relacionada con la hiperuricemia. Reivindicación 1: Una composición farmacéutica para tratar o prevenir una enfermedad relacionada con la hiperuricemia de un sujeto, caracterizada porque comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico o una sal farmacéuticamente aceptable de este, donde el ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico o una sal farmacéuticamente aceptable de este en la composición farmacéutica se administra por vía oral sujeto en una dosificación de 50 a 200 mg/día, El sujeto tiene una tasa de filtración glomerular estimada (eGFR) de menos de 90 mL/min/1,73 m².
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210077709 | 2021-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126153A1 true AR126153A1 (es) | 2023-09-13 |
Family
ID=84525806
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101577A AR126153A1 (es) | 2021-06-15 | 2022-06-15 | Una composición farmacéutica que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP4360631A1 (es) |
| JP (2) | JP2024520150A (es) |
| KR (2) | KR20220168173A (es) |
| CN (2) | CN117412746A (es) |
| AR (1) | AR126153A1 (es) |
| AU (2) | AU2022294728A1 (es) |
| BR (2) | BR112023026432A2 (es) |
| CA (2) | CA3221533A1 (es) |
| CL (1) | CL2023003514A1 (es) |
| CO (2) | CO2023016621A2 (es) |
| MX (2) | MX2023014357A (es) |
| PE (2) | PE20240242A1 (es) |
| TW (2) | TW202308611A (es) |
| WO (2) | WO2022265378A1 (es) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101679251B (zh) * | 2007-04-11 | 2013-10-02 | 橘生药品工业株式会社 | (氮杂)吲哚衍生物及其医药用途 |
| TWI423962B (zh) | 2009-10-07 | 2014-01-21 | Lg Life Sciences Ltd | 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物 |
| TWI548630B (zh) | 2011-04-06 | 2016-09-11 | Ｌｇ生命科學有限公司 | １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法 |
| JP2016520133A (ja) * | 2013-05-31 | 2016-07-11 | タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド | キサンチンオキシダーゼ阻害剤を用いた治療方法及びそれを含む組成物 |
| CN106008488B (zh) * | 2016-05-20 | 2018-10-30 | 广东东阳光药业有限公司 | 氰基吲哚类衍生物及其制备方法和用途 |
-
2022
- 2022-06-15 CN CN202280034026.0A patent/CN117412746A/zh active Pending
- 2022-06-15 MX MX2023014357A patent/MX2023014357A/es unknown
- 2022-06-15 MX MX2023014359A patent/MX2023014359A/es unknown
- 2022-06-15 EP EP22825301.9A patent/EP4360631A1/en active Pending
- 2022-06-15 WO PCT/KR2022/008444 patent/WO2022265378A1/ko active Application Filing
- 2022-06-15 AU AU2022294728A patent/AU2022294728A1/en active Pending
- 2022-06-15 TW TW111122220A patent/TW202308611A/zh unknown
- 2022-06-15 AR ARP220101577A patent/AR126153A1/es unknown
- 2022-06-15 PE PE2023003221A patent/PE20240242A1/es unknown
- 2022-06-15 AU AU2022292402A patent/AU2022292402A1/en active Pending
- 2022-06-15 JP JP2023574689A patent/JP2024520150A/ja active Pending
- 2022-06-15 CN CN202280039108.4A patent/CN117425477A/zh active Pending
- 2022-06-15 KR KR1020220072509A patent/KR20220168173A/ko not_active Application Discontinuation
- 2022-06-15 TW TW111122219A patent/TW202304428A/zh unknown
- 2022-06-15 EP EP22825305.0A patent/EP4344701A1/en active Pending
- 2022-06-15 WO PCT/KR2022/008450 patent/WO2022265382A1/ko active Application Filing
- 2022-06-15 CA CA3221533A patent/CA3221533A1/en active Pending
- 2022-06-15 KR KR1020220072501A patent/KR20220168172A/ko not_active Application Discontinuation
- 2022-06-15 PE PE2023003210A patent/PE20240241A1/es unknown
- 2022-06-15 JP JP2023574504A patent/JP2024520138A/ja active Pending
- 2022-06-15 BR BR112023026432A patent/BR112023026432A2/pt unknown
- 2022-06-15 BR BR112023026415A patent/BR112023026415A2/pt unknown
- 2022-06-15 CA CA3221017A patent/CA3221017A1/en active Pending
-
2023
- 2023-11-24 CL CL2023003514A patent/CL2023003514A1/es unknown
- 2023-11-30 CO CONC2023/0016621A patent/CO2023016621A2/es unknown
- 2023-11-30 CO CONC2023/0016596A patent/CO2023016596A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202308611A (zh) | 2023-03-01 |
| WO2022265382A1 (ko) | 2022-12-22 |
| CN117425477A (zh) | 2024-01-19 |
| TW202304428A (zh) | 2023-02-01 |
| CA3221017A1 (en) | 2022-12-22 |
| EP4344701A1 (en) | 2024-04-03 |
| JP2024520138A (ja) | 2024-05-21 |
| CO2023016621A2 (es) | 2023-12-11 |
| MX2023014359A (es) | 2023-12-15 |
| PE20240242A1 (es) | 2024-02-16 |
| CL2023003514A1 (es) | 2024-05-03 |
| MX2023014357A (es) | 2023-12-15 |
| PE20240241A1 (es) | 2024-02-16 |
| AU2022292402A1 (en) | 2023-12-14 |
| CA3221533A1 (en) | 2022-12-22 |
| CN117412746A (zh) | 2024-01-16 |
| AU2022294728A1 (en) | 2024-01-04 |
| KR20220168173A (ko) | 2022-12-22 |
| KR20220168172A (ko) | 2022-12-22 |
| JP2024520150A (ja) | 2024-05-21 |
| BR112023026432A2 (pt) | 2024-03-05 |
| EP4360631A1 (en) | 2024-05-01 |
| WO2022265378A1 (ko) | 2022-12-22 |
| BR112023026415A2 (pt) | 2024-03-05 |
| CO2023016596A2 (es) | 2023-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023002662A5 (es) | ||
| JP5296557B2 (ja) | 流涎症の治療のためのアルファ−２受容体アゴニスト（クロニジン）と抗ムスカリン剤（オキシブチニン）との組み合わせ | |
| JP2019517542A5 (es) | ||
| US10052281B2 (en) | Local administration-type pharmaceutical for improving dysphagia | |
| JPH10167960A (ja) | 肝細胞ガン再発抑制剤 | |
| TW202203946A (zh) | 用於人或動物之慢性或急性之病毒感染症及/或敗血症之預防或治療的組成物 | |
| AR126153A1 (es) | Una composición farmacéutica que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-carboxílico | |
| TW473389B (en) | New pharmacological use of AII-receptor antagonists | |
| JP7110196B2 (ja) | カルバメート化合物を含む非経口用液剤 | |
| CA2444839A1 (en) | Ambroxol for the treatment of inflammation in the pharynx | |
| JP4463206B2 (ja) | グリチルリチン高濃度製剤 | |
| EP1121110B1 (en) | Use of metformin to counteract weight gain associated with valproate and other psychotropic medications | |
| US9974768B2 (en) | Pharmaceutical for improving dysphagia | |
| CN112512526B (zh) | 化合物a与化合物b联合在制备治疗痛风或高尿酸血症的药物中的用途 | |
| EP2184284B1 (en) | Preventive, inhibitor or remedy for cerebral aneurysm comprising ibudilast as an active ingredient | |
| US8952011B2 (en) | Compositions and methods for the treatment of nasal conditions | |
| WO2023201390A1 (en) | Aqueous quetiapine solutions | |
| US4757075A (en) | Tetrazolylquinazolinones as anti-hyperuricemic agents | |
| JP2021161105A (ja) | ヒト又は動物の慢性若しくは急性のウイルス感染症及び／又は敗血症の予防若しくは治療のための組成物 | |
| UA120764U (uk) | Лікарський препарат знеболювальної та спазмолітичної дії "фентаніл" | |
| JP2006117569A (ja) | ステロイド依存性あるいはステロイド抵抗性潰瘍性大腸炎治療薬 | |
| JP2006089439A (ja) | 肝線維化抑制剤 | |
| JP2004143068A (ja) | インフルエンザ脳炎・脳症の予防及び／又は治療のための医薬 | |
| JPWO2005117853A1 (ja) | 高脂血症治療剤及び糖尿病治療剤 | |
| RU2003107504A (ru) | Лекарственное средство для лечения хронического обструктивного бронхита |